Roivant Sciences Ltd.
$21.37B- Market cap
- $25.25B
- Debt
- +$412.94M
- Cash
- −$4.29B
Capital structure 98% equity / 2% debt · EV / Revenue 2586.72x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: ROIV stock price at premium vs FICO $34.95 current versus $0.12 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FICO's multiple
Implied fair value · at ROIV's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · FICO FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 2586.72x
Capital structure 85% equity / 15% debt · EV / Revenue 11.78x · EV / EBITDA 25.32x
FICO carries the larger enterprise value at $23.46B against $21.37B; FICO trades on the lower EV / Revenue multiple (11.78x vs 2586.72x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
FAIR ISAAC CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.09x
-1.98x
Net debt / EBITDA
Leverage against operating earnings
24.52x
3.58x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$134.14M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
MSCI Inc.
ROIV vs MSCI
MOODYS CORP /DE/
ROIV vs MCO
SS&C Technologies Holdings Inc
ROIV vs SSNC
Verisk Analytics, Inc.
ROIV vs VRSK
EQUIFAX INC
ROIV vs EFX
$412.94M
$3.46B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.